 Hi guys, how you doing? This is Rich here and we have a Rich TV Live. And today I'm going to talk to you about another super hyper growth stock that I think has enormous potential and enormous upside, Mitocene Innovations. Right, Mitocene Innovations. Now this is not the first time I've talked about this company, I've talked about them before. They've made some big runs and recently they've had some big catalysts coming. So I wanted to talk to you about it today and break down why I think this company has a chance to be a success and why I believe that they are currently undervalued, underappreciated and underexposed. Hope you had a great weekend, hope you're having a great morning. Here is Mitocene Innovations. This is their website, mitocene.com. Mitocene Medicine Evolved Revolutionizing Nature's Medicine for Mental Health and Vitality. And if you guys would like to join the chat, just join the chat. And if you have any questions, please put it in the chat so that we can discuss any of your key questions. If you liked the video, please smash the like button, comment on the video, share the video everywhere and subscribe. And remember, Rich TV Live is strictly for education and entertainment purposes. Always do your due diligence, always do your research before you invest in anything that we talk about here in Rich TV Live. What I'm going to do today is I'm going to go through some of the big news and some of the information on Mitocene Innovations Group, Inc. You can also see they have some big news today. I'll just read the news right now. Mitocene fully completes the first ever international export of psilocybin, mushrooms, and solidifies its clinical and commercial supply chain. This is literally big breaking news this morning. I might as well break it first because that's just what we do. Mitocene Innovations Group, MYCO in Canada, MYCOF in America, ONFA in Frankfurt, Germany, an emerging biopharma company in the life sciences category committed to the research and development, production, and acceptance of alternative natural source medicine for mainstream use, has completed the world's first international leg export of dried psilocybin mushrooms. That's right. The world's first international legal export of dried psilocybin mushrooms. In December, 2020, company announced the completion of its first commercial harvest of 20 kilograms, 44 pounds of psilocybin mushrooms at a private mycology focused research and cultivation facility in Jamaica. The first shipment of the harvest has now been received at Mitocene's Canadian Current Good Manufacturing Practice, CGMP facility, which has a Health Canada Schedule I dealers license attached to it, allowing for legal import, export, research, and development, cultivation, product development, and commercial sale of active psychedelic medicinal compounds. And I told you guys psychedelics is a brand new sector. It's just getting started. I think the upside is tremendous. The fact that these are companies now that I've been bringing to you guys that are actually making revenue is key to the growth of the sector and key to these companies. Good morning, Daniel. Good morning, Seth. Good morning, BK. Hope you guys are having a great day. Love to know what you think about Mitocene innovations. This milestone is significant to our 2021 bulls as we are now able to access a quality source of much needed product for both our own research purposes as well as provide CGMP naturally derived psilocybin to sell and transfer to other licensed research facilities around the globe. Our team has spent significant time working with various government agencies to create and develop sound protocols to ensure a smooth flow of biomass that is in full compliance with all federal laws. This is the first and only solidified commercial supply chain of psilocybin mushrooms and we believe this supply chain will open up many doors to potentially collaborate and participate in initiatives that we will find potentially promising, said Joshua Barch, CEO and Chairman of Mitocene. We have made significant progress towards having the first IND number on a 99.9% pure psilocybin product that the synthetic form mimics. We believe our natural source psilocybin that is both significantly less costly and more efficient than the synthetic form will prove to be a better overall option to meet the current market demand as well as voids any and all potential patent claims. This marks a milestone of fulfilling on the promise of creating a fully vertical and uninterrupted global supply chain. Wow, big, big news for Mitocene. In the most potential psychedelic mushrooms, in the most potent psychedelic mushrooms, psilocybin is typically only around 1% of its total mass. This means that as much as 99% of the mushroom is composed of vegetative matter plus other potential active medicinal compounds. At our lab, we have already discovered multiple other active compounds separate from psilocybin and psilocin from just our initial psychedelic mushroom analysis. Based upon our preliminary studies, we believe that this could have more effective results than just single molecular synthetic psilocybin. This supply chain will give us unrestrictive, scalable access, including numerous types of unique psychedelic mushroom spaces, species native to Jamaica. This should be significant. It should significantly increase our research and development and production efforts with some of the best types of mushrooms that we know of, said Damon Michaels, Mitocene's co-founder and chief operating officer. He continued, throughout history, we have seen many historical instances involving the use of psychedelic medicine. More so for the use of psychedelic mushrooms to be used as safe and effective therapeutic medicine to help improve mental injuries or expand one's overall consciousness. Today, we are able to take this ancient form of holistic medicine and pair it with modern technology to better understand its active ingredients and how they specifically interact with the brain and body to produce the best, most controllable and beneficial result possible. We might have seen to be able to create the world's first legal global supply chain of nature-sourced psilocybin to not only meet its own needs, but to supply to other licensed research organizations, universities and healthcare facilities around the world. We hope to finally break the barrier of stigma and help people obtain mainstream access to this sacred medicine and turn it back into a traditional therapy about Mitocene Innovations Group. Mitocene Innovations Group, MYCO in Canada, MYCOF in America, ONFA in Frankfurt, Germany is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company's world-renowned Medical and Scientific Advisory Board is building out a robust R&D pipeline of nature-sourced psychedelic assisted therapeutics, novel compounds, therapy protocols and unique delivery systems. Mitocene has exclusive access to a full CGMP-certified pharmaceutical manufacturing compounds facility with the ability to import, export, cultivate, extract, isolate and analyze active mushroom compounds with full government approval through Health Canada. Mitocene also operates out of a state-of-the-art mycology lab in Denver, Colorado to focus on genetic research for scaling commercial cultivation of rare non-psychedelic medicinal mushrooms. At the heart of Mitocene's core philosophy is that psychedelic assisted psychotherapy will continue to gain acceptance in the medical community with many of the world's best-accredited research organizations demonstrating its remarkable clinical effectiveness. Mitocene recognizes the responsibility associated with psychedelic assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology and global supply. Mitocene also has successfully completed multiple acquisitions since inception. That's the big breaking news. Mitocene, Innovations, MYCO in Canada, MYCOF in America, ONFA in Frankfurt, Germany. Put on your watch list, put on your radar. This is big, big news for Mitocene. This is their website, mitocene.com. You can learn about them, just click on About Us, learn the whole story, learn about their portfolio, their story, for investors, news and media and their leadership team right on their website. What I want to do is I want to go through the chart a little bit here. So I always like to mark the low, low and the high, high anytime I look at a stock. So first thing I do is I mark the low, low and you could see that in November I hit a low, low of 16 cents. That was clearly the best time to enter the stock. And it first started off really high. It actually started off at 115 last summer, last June. Been as high as 115, been as low as 16, currently at 46. So it's closer to the low, low than it is the high, high which to me is signaling that it could be in a buy zone with tremendous upside from here. Typically when I see a stock that's just kind of getting started and it's already been higher, to me it's kind of setting a tone of where it could go. I'm not saying it's gonna stay at a dollar but I believe it could literally go to a dollar. So anyone that gets in at these levels I believe there's at least 100% upside from here. And I'm not saying it's gonna happen overnight. I'm not gonna say it's gonna happen today. I'm not gonna say it's gonna happen tomorrow. Past performance is not an indication of future results. I don't know where it's going to go, 100% and when but as an investor trying to look for clue reading the news, I'm looking at the chart and I'm trying to understand the company and I'm trying to understand where it's been, where it's gone and where it's going. And typically trends are your friend and trends have a way of continuing. And you can see here very similarly in the United States been as high as 89 cents and recently been as low as 12, been as low as 3 cents really, which was an amazing entry, been as high as 89, right? And currently at 36. So still a lot upside from here in my opinion we've seen it higher, we've seen it lower. I believe with this news and with growing revenue and the fact that they are going to be expanding internationally and generating revenue could be a big catalyst for this company and down the road at some point I believe we will see this at least a dollar. So love to know your opinion on this. If you agree with me or disagree with me, love to know comment on the video, share the video everywhere and subscribe. And if you haven't smashed the like button please smash the like button. I work really hard to bring you this type of information every single day and bring you really good companies. This is a company that I've brought you previously. It did really well. It's kind of come back down and I think now's the time to look at it again. Psychedelic mental health solutions gaining steam with elite athletes and researchers. So this is a new sector. It reminds me a lot of the cannabis sector when it first started in 2015, 2016 had an epic run in 2017 and then it consolidated. It's now consolidated, we're in 2021. We still see some of the top cannabis companies do extremely well, but for the most part all the others have either struggled or consolidating. And what's happening now in the psychedelic space is that a whole bunch of new players are coming to the forefront, trying to be the leaders and Midasin has a chance to be really good. So Midasin Innovations Inc, MYCO in Canada, MYC-OF in America, ONFA in Frankfurt, Germany is positioned at the center of the biggest ever breakthroughs in natural medicine. Right, prior to his monumental comeback at the age of 54 former world heavyweight boxing champion Mike Tyson, who I'm a huge fan of was delivered a message from a frog. More precisely, he received the message from a psychedelic source from the Veminist Colorado River Toad also known as the Sonoran Desert Toad known as Five-Myo DMT, aka Myo or Frog Venom. I took the Five-Myo DMT and the medicine told me to get into shape, Tyson said to USA Today. It really blew my mind. It told me to come back and start getting into shape. With the help of psychedelics, Tyson lost more than a hundred pounds for a major exhibition bout against Roy Jones Jr., which I watched and I felt that Tyson won that fight. They called it a draw, probably because they want to do it again. His first fight in 15 years, said to be more transcendent and less visual than its plant-based cousin DMT, Five-Myo DMT can be a stronger experience for some. Most Five-Myo trips are kept to under an hour and require far smaller dose sizes than other psychedelics. But even more impressive is the fast acting psychedelics potential which researchers at John Hopkins have discovered can bring about improvements in depression and anxiety. So imagine psychedelics changing the world, eliminating all the pharmaceutical drugs that are being used for depression and anxiety and replacing them with psychedelics. This is the direction that psychedelics is going. That's why I'm so excited about psychedelics and I believe that the future for psychedelics is great. That's why I'm personally buying psychedelic stocks. I'm personally buying psychedelic stocks. Our community is personally buying psychedelic stocks. The potential for psychedelics to treat mental health issues is truly on the precipice of a major breakout, especially as acceptance of this once taboo form of treatment begins to make its way into mainstream medicine conversations. Tyson is not alone being among athletes, elite athletes who've looked into psychedelics to turn their life around. Former Los Angeles Laker star Lamar Odom who's had many issues with drug abuse and substance abuse successfully use the psychedelic drug, catamine and Obogaine combat his drug addiction creating the drugs with saving, crediting the drugs with saving his life. There are other success stories including those of NHL enforcer Riley Cote, Daniel Carcerillo, former NFL player Kerry Rhodes and former UFC MMA fighters Ian McCall and Dean Lister utilizing previously taboo treatments such as ayahuasca, catamine, Ibogaine, psilocybin, MDMA and now five MEO DMT. Now these treatments are shifting from anecdotal to a potential commercial reality with the advent of clinical trials being carried out by some of the world's top psychedelics and mental health researchers. And in an incredible opportunity for investment is coming into view. Some analysts are projecting the psychedelics medicine industry to hit 6.85 billion by 2027. I knew psychedelics ETF began trading in January ESYK is the symbol for the new psychedelics ETF and strong contenders are emerging to meet the demand with two already crossing the US one billion market cap threshold. Among the group is one emerging company backed by a world renowned medical and scientific advisory board that deserves much more attention. The company is Mitocin Innovations Group which I'm bringing to you today. Now those companies that are over one billion are Compass Pathways, the MPS and you mentioned it here, Mind Medicine, MMED, M-M-E-D-F which I brought to you guys first at 30 cents and has been a 15 bagger meaning it's up 15 times if you had bought that when I brought it to you first you would be up 15 times on your money. Good morning, Amphold Drew. You're getting NEO today, cool, cool. GN Franco, how you doing? Where do I think PSYC can go? I think you can go to at least a dollar this year. Hey, good morning, Robert. Hope you're having a great day. Hope you guys are all ready for a big week. Obviously last week was a tough week, turbulent week. See a lot of YouTubers calling it a crash. I hardly call it a crash. I call it a red day, that's what it was. Looks as though we're in for a green day today. So I hardly call us being at 30 or 31K Dow crash. The market is at all-time highs. We came back from 32K Dow to just under 31K Dow. That's not a crash for me. That's a pullback, that's a red day. I hardly think that's a crash. Markets at all-time highs, markets extremely bullish and the market had to just go for a pit stop so that it could continue going in its direction. And I believe it will. I think the market's very strong right now and I believe that the market will continue to gain steam especially with stimulus coming. Trillions of dollars in stimulus in America. I believe that's very bullish for the markets. And hopefully we continue to see a strong market because we're all at home and we have to find ways to make money. And in my opinion, the best way to make money is to trade, trade stocks, trade cryptocurrencies. And that's what we do. We do that at our trading club. If you'd like to learn to join our trading club, you can richpicksdaily.com. We are growing very quickly. We've got members in over 20 countries worldwide and we are literally growing every day and we're looking for some of the smartest trading minds in the world to join our community. And we're looking for people that want to learn how to trade to join our community so that we can teach you how to be one of the top traders on the planet. That's the plan at Rich TV Live. So let's just go through this a little bit more. So Mitocene Innovations Inc. is led by an expert team of researchers and marketers including a seven-time, that's right, seven-time Nobel Prize nominee, Red Bull's former chief marketing officer, multiple high-level partners, military scientists, university researchers and already has a distribution arm at its disposal that's currently serving tens of thousands of retail outlets. These guys are building dynasty, currently trading at around 46 cents. You'll think it's cheap with a market cap still slightly above 100 million. Mitocene is a prime breakout star in the making. And if this goes to a one billion market cap, that means we have room for this stock to grow 9x, 900% from here, which would take the stock to about $350 to $4, and that would be a huge return for investors. Obviously it's not gonna happen overnight that they're gonna grow to a one billion market cap, but if you believe that they have a chance to grow to a one billion market cap, this could be a nice good long-term play for investors. With multiple clinical trials in the pipeline, including involvement with a large-scale microdose study cosponsored by the National Institute of Health Research at Imperial College of London, a phase to a clinical study on PTSD in veterans, EMS and frontline workers, and the first-of-its-kind microdose study in Australia. Mitocene is at the forefront of much of the world's most important psychedelic research. This is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. Coming off a freshly closed-bought deal financing, guys, they just raised 17.5 million. 17.5 million for a stock at 46 cents. I think we know this is going to at least a dollar. Mitocene Innovations Group, M-Y-C-O, M-Y-C-O-F-O-N-F-A has filed for uplisting to the NASDAQ and was just added to world's first-ever psychedelics EPF. So if they're planning to go to the NASDAQ and the stock's at 46 cents, something has to give. Because in order for them to go to the NASDAQ, they're gonna have to be at least four to five bucks. With only a number of shareholders currently holding equity in the company and money in the bank, it's clear that Mitocene Innovations Group is worth a deeper dive. Now let's get into the details of this promising company that's in a market that's already created to U.S. one billion market cap psychedelic companies. They are leading the renaissance of cutting-edge medicines. And you can see here first legal nature source psilocybin extraction, first legal commercial export of psilocybin mushrooms, launched the first psychedelics-focused telehealth platform called MindLeap Health, launched first-ever psilocybin clinical trials with veterans with PTSD indications, first company to achieve CGMP status of psychedelic mushrooms, products for production, sale and export, discovered several novel active molecules never found in natural-sourced fungal sources, birth of its kind, microdose study at Mercury University in Australia. So let's talk about seven reasons why Mitocene Innovations Group could potentially be the top psychedelic stock of 2021. Wow, can you imagine that? Ali says, thinking of swapping my PSYC for Neon. I like them both. I think both have huge potential. PSYC just raised $6 million and I think the upside and the future for them is bright. So let's talk about the seven reasons why Mitocene Innovations Group could potentially be the top psychedelic stock of 2021. A world-renowned medical and scientific advisory building out a robust R&D pipeline of net nature-sourced psychedelic therapeutics, novel compounds, therapy protocols and unique delivery systems, exclusive access to a full CGMP-certified pharmaceutical manufacturing facility with the ability to import, export, cultivate, extract, isolate and analyze active mushroom compounds with full government approval through Health Canada. Operates out of a state of the art, my college lab in Denver, Colorado to focus on genetic research for scaling commercial cultivation of rare non-psychedelic medicinal mushrooms. I love this company. Love what these guys are doing. This is a big list of six stats that they're having and the reality is, in my opinion, this is just getting started. This is clearly just getting started. Seven patent-pending applications that represent thousands of inventions with multiple layers of protection on the company's proprietary medical development pipeline. The proprietary digital health platform MindLeap allows Mitocene to generate revenue in the fast growing US 41.4 billion telemedicine market. And that's huge because very few of these companies are generating revenue. In fact, I don't think any of them are yet. Numerous clinical trials. I'm talking about psychedelic stocks. Numerous clinical trials are currently underway, including a large-scale microdose study faced to a clinical trial on PTSD in veterans, EMS and frontline workers, a first-of-its-kind microdose study and preclinical animal work for late-stage addiction study aiming at a mechanistic understanding of psilocybin. Number seven, tremendous growth potential. And this is why I'm really excited about psychedelic stocks. Like I said, it reminds me of the early stage of the cannabis sector. And clearly, we've seen a cannabis sector that's had some ups and downs, but some of the best stocks and the best companies have been huge success stories. Remanded growth potential at its current market cap is still under 90 million Canadian, where three of its closest comparables, also in phase two A and B clinical trials, like Mitocin, are currently valued more than three times higher with two valued at more than one billion. So why is this so important? They are combating the mental health crisis with psychedelics. COVID-19 is taking its toll on all of us, including rising deaths of despair and an urgent mental health crisis among health workers. Recent study that screened 402 survivors of COVID-19 found that 55% presented a clinical score for at least one mental disorder, including anxiety 42%, insomnia 40%, depression 31%, PTSD 28% and OCD 20%. Anxiety disorders are the most common mental illness in the United States, affecting 40 million adults or 18.1% of the population every year. Sadly, only 36.9% of those suffering receive treatment and more than half of people who take antidepressants never get relief. In cases of veterans with PTSD, several patients are put on SSRIs. However, only 20 to 30% of patients achieve complete remission. Something needs to change. Thankfully, we are witnessing what's being deemed a paradigm shift in psychiatric research and development that paradigm shift is coming from psychedelics. So I believe this is the future of psychedelics. I'm not gonna go through everything. I'm not gonna go through the entire website, but I wanna make sure you guys are aware of Mitocine, okay? This is a company that I think has so much potential, MYCO and I broke down all the different reasons why. And you can see here that the stock is just starting to trade for the day. So hope you guys have a great trading day. MYCO in Canada, MYCOF in America. Put it on your watch list, put it on your radar. I think the upside for them is tremendous. Now, I can't guarantee that it's gonna continue to go up, past performance is not always an indication of future results, but it's one that I believe in. And I think the upside is tremendous. As you can see, other psychedelic stocks that I've talked about are having big days. Here we are, PSYC, we brought it to you guys first. They're having a monster day, as you can see up already. Gold Mountain Mining, another one that I brought you guys. They're up, they're having a big day. Pure Extracts Pull, they're up, they're having a big day. Neon, I brought you guys this pick on my top 10. They're up, they're having a big day. HP, I put them in my top 10. They're up, they're having a big day. I brought news on CLC this weekend. They're up, they're having a big day. I brought news on Tatlifestyle and Wellness. They're up, they're having a big day. I brought, I told you guys btcc.u was my top Bitcoin play, blockchain play and the only, first only ever Bitcoin ETF in the world. They're up, they're having a big day. You guys see the trend? Same trend, right? ENBI, another psychedelics play. They're up, they're having a nice day. So I'm gonna let you guys go now. I'm gonna get back to the markets. A lot of our picks are up today. Congratulations to investors all over the world. Is your board rich or rich to be live? If you're not winning, you're not watching. We bring you the winners and we bring them to you first. As you can see, we bring you MYCO, they're up 5% and at 49 cents. Congratulations to investors all over the world. If you're not winning, you're not watching. I told you guys, we're bringing the winners and we bring them to you first. We've been doing this since 2017 and we just getting started. Have a great day everybody. You're not winning, you're not watching. We're bringing the winners and we're bringing them to you first. Let me know what you guys think. Might have seen innovations. Stay tuned. I got more tricks up my sleeves. I got more picks and I got some more hits. You're a board rich from Mercy to be live. Bring the winners and we bring them to you first. If you're not winning, you're not watching. MYCO, MYCOF. Let me know what you think. I'm out. Have a big day everybody. We'll see you soon. All we do is bring your winners.